Clinical trials and late‐stage drug development for A lzheimer's disease: an appraisal from 1984 to 2014 LS Schneider, F Mangialasche, N Andreasen, H Feldman, E Giacobini, ... Journal of internal medicine 275 (3), 251-283, 2014 | 759 | 2014 |
Volume, neuron density and total neuron number in five subcortical regions in schizophrenia P Kreczmanski, H Heinsen, V Mantua, F Woltersdorf, T Masson, N Ulfig, ... Brain 130 (3), 678-692, 2007 | 223 | 2007 |
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ... European Psychiatry 54, 71-76, 2018 | 221 | 2018 |
Identification and validation of biomarkers for autism spectrum disorders E Loth, W Spooren, LM Ham, MB Isaac, C Auriche-Benichou, ... Nature reviews Drug discovery 15 (1), 70-70, 2016 | 188 | 2016 |
Is it time to revise the diagnostic criteria for apathy in brain disorders P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ... The 2018 international consensus group. Eur Psychiatry 2018; 54: 71 76, 2018 | 107 | 2018 |
Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice: position paper of the Dementia and Cognitive Disorders Panel of … MT Ferretti, J Martinkova, E Biskup, T Benke, G Gialdini, Z Nedelska, ... European journal of neurology 27 (6), 928-943, 2020 | 96 | 2020 |
Does psychomotor retardation define a clinically relevant phenotype of unipolar depression? S Calugi, GB Cassano, A Litta, P Rucci, A Benvenuti, M Miniati, L Lattanzi, ... Journal of affective disorders 129 (1-3), 296-300, 2011 | 51 | 2011 |
Microvessel length density, total length, and length per neuron in five subcortical regions in schizophrenia P Kreczmanski, H Heinsen, V Mantua, F Woltersdorf, T Masson, N Ulfig, ... Acta neuropathologica 117, 409-421, 2009 | 49 | 2009 |
Drug development for autism spectrum disorder (ASD): progress, challenges, and future directions JT McCracken, E Anagnostou, C Arango, G Dawson, T Farchione, ... European Neuropsychopharmacology 48, 3-31, 2021 | 36 | 2021 |
Search for peripheral biomarkers in patients affected by acutely psychotic bipolar disorder: a proteomic approach L Giusti, V Mantua, Y Da Valle, F Ciregia, T Ventroni, G Orsolini, ... Molecular biosystems 10 (6), 1246-1254, 2014 | 27 | 2014 |
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective V Mantua, C Arango, P Balabanov, F Butlen-Ducuing Nature Reviews Drug Discovery 20 (2), 83-84, 2021 | 22 | 2021 |
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease M Haas, V Mantua, M Haberkamp, L Pani, M Isaac, F Butlen-Ducuing, ... Nature Reviews Drug Discovery 14 (4), 221-222, 2015 | 18 | 2015 |
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease P Bradley, R Akehurst, C Ballard, S Banerjee, K Blennow, J Bremner, ... Alzheimer's & Dementia 11 (4), 455-461, 2015 | 15 | 2015 |
Il Disturbo Post-traumatico da Stress nella vita quotidiana. PP Colombo, V Mantua Rivista di psichiatria, 2001 | 10 | 2001 |
Bipolar spectrum: just broadening or an integration between categories and dimensions? GB Cassano, V Mantua, A Fagiolini World Psychiatry 10 (3), 192, 2011 | 6 | 2011 |
Sustainable Reimbursements: Towards a Unified Framework for Pricing Drugs with Significant Uncertainties S Chassang, V Mantua, E Snowberg, E Xoxi, L Pani CESifo Working Paper Series, 2018 | 4 | 2018 |
Manic episode after ventricular-peritoneal shunt replacement in a patient with radiation-Induced hydrocephalus: the role of lifetime subthreshold bipolar features A Callari, V Mantua, M Miniati, A Benvenuti, M Mauri, L Dell'Osso Case Reports in Psychiatry 2014, 2014 | 4 | 2014 |
Accelerating medicines partnership® Schizophrenia (AMP® SCZ): Rationale and study design of the largest global prospective cohort study of clinical high risk for psychosis CMJ Wannan, B Nelson, J Addington, K Allott, A Anticevic, C Arango, ... Schizophrenia bulletin 50 (3), 496-512, 2024 | 2 | 2024 |
Regulatory considerations in drug development for autism spectrum disorders V Mantua, T Farchione European Neuropsychopharmacology 48, 47-48, 2021 | 1 | 2021 |
P. 3. c. 045 Treatment of agitation caused by severe mental illness: data from the South London and Maudsley intensive care units trial evaluation (SLAMICUTE) study V Mantua, MJ Travis, Z Atakan, MB Isaac, MT Isaac, S Smith, D Gilbert, ... European Neuropsychopharmacology, S420-S421, 2006 | 1 | 2006 |